Issuu on Google+

MarketsandMarkets Presents

Asia-Pacific Nuclear Medicine/Radiopharmaceutical Market worth $825 Million By 2017


The "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C13) – Forecast to 2017 " analyzes and studies the major market drivers, restraints, and opportunities in Japan, China, India, South Korea, Indonesia, Malaysia, Australia, New Zealand, & Rest of Asia Browse 146 market data tables with 27 figures spread through 313 pages and indepth TOC on Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017 Early buyers will receive 10% customization on reports. Download a free copy of PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=1140


Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimers disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012. It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 30% in the developing markets of the Asia-Pacific region, including India, Australia, and South Korea, between 2010 and 2030. The scheduled shutdown of the NRU reactor in Canada in 2016 and OSIRIS in France in 2018 will not have any major impact in the near future, since demand in this geographic region is compensated by local reactors such as ANSTO. Radiopharmaceuticals are under clinical trials to extend applications. For instance, preference for radiopharmaceuticals in neurological indications such as Alzheimers, Parkinsons, and dementia are increasing besides conventional applications such as cardiology and oncology. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.


Radiopharmaceuticals Market Share Analysis, By Key Player (2012)

Source: Annual Reports, SEC Filings, OECD Publications, WNA, EANM, IAEA, SNMMI, Nuclear Medicine Associations, Experts Interviews, MnM Analysis


Contact Us Mr. Rohan North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas, TX 75252 Tel: +1-888-600-6441 Email: sales@marketsandmarkets.com http://www.linkedin.com/company/marketsandmarkets


About MarketsandMarkets MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.


Asia-Pacific Nuclear Medicine/Radiopharmaceutical Market worth $825 Million By 2017